In order to validate the development of drug tolerance phenotypes in our studies, we examined EGFR-mutant PC9 NSCLC cells treated with the EGFR inhibitor gefitinib, exactly as described in the study by Sharma et al. [1]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.